What are the recommended evaluation steps and treatment options for bronchiectasis?

Bronchiectasis: Evaluation and Treatment

All adults with bronchiectasis should be taught airway clearance techniques by a respiratory physiotherapist and perform them 1-2 times daily, with long-term macrolide antibiotics (azithromycin 250mg three times weekly) strongly recommended for patients experiencing 3 or more exacerbations per year. 1, 2

Initial Diagnostic Evaluation

The minimum essential testing bundle for newly diagnosed bronchiectasis includes 1, 3:

• Complete blood count with differential
• Serum immunoglobulins (IgG, IgA, IgM) and functional antibodies to identify immunodeficiency requiring replacement therapy
• Testing for ABPA (IgE, Aspergillus-specific IgE, Aspergillus IgG)
• Sputum culture for routine bacteriology and fungal culture
• Three sputum samples for mycobacterial culture (if no spontaneous sputum, consider induced sputum or bronchoscopy with BAL)

Additional targeted testing based on clinical features:

• Cystic fibrosis screening if appropriate clinical features
• Assessment for GORD and inflammatory bowel disease
• Evaluation for autoimmune conditions and rheumatoid arthritis
• Sinus disease assessment (chronic rhinosinusitis is common)

Baseline imaging should include CT chest (with contrast if pulmonary embolism suspected), chest X-ray for future comparison, and consideration of echocardiogram to assess left ventricular function and pulmonary hypertension 1.

Stepwise Treatment Algorithm

Step 1: Foundation for All Patients

Airway clearance is non-negotiable. Every patient should receive assessment and instruction from a respiratory physiotherapist on airway clearance techniques 1, 2. Options include:

• Active cycle of breathing with forced expiration technique (huff)
• Autogenic drainage
• Positive expiratory pressure devices
• Modified postural drainage (no head-down tilt to avoid GORD exacerbation)
• High-frequency chest wall oscillation or intrapulmonary percussive ventilation as alternatives

Duration: Minimum 10 minutes up to 30 minutes, continuing until two clear huffs/coughs or fatigue develops. Frequency should be individualized but typically once or twice daily 1.

Pulmonary rehabilitation is strongly recommended for patients with impaired exercise capacity or dyspnea, with demonstrated high-quality evidence for benefit 3, 2.

Step 2: If ≥3 Exacerbations/Year Despite Step 1

• Physiotherapy reassessment
• Consider mucoactive treatment trial (humidification with sterile water or normal saline; hypertonic saline) 1
• Do NOT use recombinant human DNase (strong evidence of harm) 1
• Pre-treat with bronchodilator before inhaled mucoactive agents, especially if FEV1 <1 liter or history of bronchospasm

Step 3: If ≥3 Exacerbations/Year Despite Step 2

This is where long-term antibiotics enter the algorithm 1:

Critical safety checks before starting long-term antibiotics:

• Ensure at least one negative NTM culture (essential for macrolides)
• Check creatinine clearance >30 mL/min (for inhaled aminoglycosides)
• Assess hearing and balance (caution with both macrolides and aminoglycosides)
• Avoid concomitant nephrotoxic medications with aminoglycosides

Treatment based on sputum microbiology:

1. If Pseudomonas aeruginosa colonization:

   • First-line: Inhaled colistin (Grade B recommendation) 1
   • Second-line: Inhaled gentamicin
   • Alternative if inhaled antibiotics not tolerated: Azithromycin or erythromycin
   • For very high exacerbation frequency: Consider adding macrolide to inhaled antibiotic 1

2. If other potentially pathogenic microorganisms:

   • First-line: Long-term macrolides (azithromycin 250mg three times weekly as pragmatic starting dose, can increase based on response) 1
   • Alternative: Long-term oral or inhaled targeted antibiotic based on sensitivities

3. If no pathogen identified:

   • Long-term macrolides 1

The 2025 ERS guidelines provide strong recommendations for long-term macrolide therapy in patients at high risk of exacerbations and strong recommendations for long-term inhaled antibiotics in chronic P. aeruginosa infection with frequent exacerbations 2.

Step 4: If ≥3 Exacerbations/Year Despite Step 3

Combine long-term macrolide AND long-term inhaled antibiotic 1

Step 5: If ≥5 Exacerbations/Year Despite Step 4

Consider regular intravenous antibiotics every 2-3 months 1

Management of Acute Exacerbations

Exacerbations are defined by: Acute deterioration over several days with worsening cough, increased sputum volume or viscosity, increased sputum purulence, with or without wheeze, breathlessness, hemoptysis, or systemic upset 1.

Antibiotic treatment:

• Obtain sputum culture before starting antibiotics when possible
• Standard duration: 14 days (always for P. aeruginosa) 1, 3
• Shorter courses may suffice in mild disease
• Empirical treatment guided by previous sputum bacteriology, then adjust based on culture results
• Intravenous antibiotics indicated for: Severe illness, resistant organisms, or failure of oral therapy (most commonly with P. aeruginosa) 1

Important caveat: Patients may respond clinically despite in vitro resistance; only change antibiotics if no clinical response 1.

Pseudomonas Aeruginosa Eradication

For new isolation of P. aeruginosa, offer eradication treatment (conditional recommendation) 3. This prevents chronic colonization which significantly worsens prognosis.

Do not offer routine eradication for other pathogens besides P. aeruginosa 3.

Anti-Inflammatory Treatments

Inhaled corticosteroids:

• Do NOT routinely use for bronchiectasis alone 1, 3
• However, maintain standard treatment for comorbid asthma or COPD 1, 3
• Consider trial in patients with inflammatory bowel disease and bronchiectasis 1

Oral corticosteroids:

• Reserved for active ABPA: 0.5 mg/kg/day for 2 weeks, then wean according to clinical response and IgE levels 1

Other anti-inflammatory agents:

• Do NOT use: PDE4 inhibitors, methylxanthines, leukotriene receptor antagonists, CXCR2 antagonists, neutrophil elastase inhibitors, or statins for bronchiectasis treatment 1, 3

Monitoring and Follow-Up

Frequency based on severity 1:

• Mild disease: Annual assessment
• Moderate-severe disease: More frequent (every 3-6 months)

Each visit should include:

• Pulse oximetry (ABG if indicated)
• Spirometry (consider lung volumes and gas transfer)
• Sputum culture and sensitivity
• Assessment of treatment adherence and technique
• Review of exacerbation frequency

For patients on long-term antibiotics:

• Review every 6 months for efficacy, toxicity, and continuing need
• Monitor sputum culture and sensitivity regularly
• Repeat sensitivity testing if clinical concern about loss of efficacy 1

Physiotherapy review:

• Within 3 months of initial assessment
• Annually as part of clinical review
• Whenever deterioration occurs 1

Critical Pitfalls to Avoid

1. Never use recombinant human DNase in non-CF bronchiectasis (Grade A recommendation against) 1
2. Do not start macrolides without excluding active NTM infection - this can lead to macrolide resistance in undiagnosed NTM disease 1
3. Do not assume in vitro antibiotic resistance means clinical failure - continue treatment if patient responding clinically 1
4. Do not neglect airway clearance - this is foundational and should never be omitted regardless of other treatments 2
5. Avoid inhaled aminoglycosides if creatinine clearance <30 mL/min 1

Special Populations

Comorbid conditions requiring specific attention:

• COPD with bronchiectasis: Higher mortality risk, requires closer monitoring 1
• Rheumatoid arthritis: Refer to chest physician before starting DMARDs or biologics 1
• Autoimmune conditions: Require long-term secondary care follow-up 1

Cross-infection considerations:

• Individual segregation based on microbiology NOT routinely required
• Apply standard cross-infection prevention principles
• If sharing facilities with CF patients, CF cross-infection guidelines prevail 1